The audience included U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This included, but was not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.
33rd Annual Meeting Organizers
- Crystal L. Mackall, MD – Stanford University
- Naiyer A. Rizvi, MD – Columbia University Medical Center
- Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
- Dario A.A. Vignali, PhD – University of Pittsburgh
Annual Program Committee
- Chair: Mario Sznol, MD – Yale School of Medicine
- Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Center
- Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT
Upon completion of this meeting, participants are able to:
- Summarize and integrate the most recent advances in tumor immunology and cancer immunotherapy into basic, clinical and translational research
- Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical applications for cancer immunotherapy
- Describe immune regulatory pathways that restrict and enhance immunity to tumor antigens, and identify respective targets for therapeutic intervention
Annual Meeting was supported in part by grants from 7 Hills Pharma, AbbVie, Amgen Inc., Astellas and Seattle Genetics, AstraZeneca Pharmaceuticals LP, Bavarian Nordic A/S, Bayer HealthCare Pharmaceuticals Inc., Bristol-Myers Squibb, Celgene Corporation, Fluidigm, Genentech, Gilead Sciences, HalioDx, Incyte Corporation, Janssen Research & Development, LLC, Lilly Oncology, Merck & Co., Inc., NanoString Technologies, Novartis Oncology, Novartis Pharmaceuticals Corporation, The Parker Institute for Cancer Immunotherapy, Pfizer, Inc., Regeneron Pharmaceuticals, TESARO, Inc., Prometheus Laboratories Inc. and Replimune.